Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1251-1263

  Ishak, K Jack ^a   Tan, Ye ^a   Glass, Jennifer ^b   Luong, Doanh ^b   Caro, J Jaime ^c,d  

^a UNITED BIOSOURCE CORPORATION   (Canada)

^b Janssen Ortho Inc   (Canada)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

case control; drug interaction; persistence; risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; RISPERIDONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; REFERENCE DATABASE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA;

EID: 48549088604     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80049-5     Document Type: Article

References (25)

1. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 50 Suppl 1 (2005)
2. Mason P., Harrison G., Glazebrook C., et al. Characteristics of outcome in schizophrenia at 13 years. Br J Psychiatry 67 (1995) 596-603
3. Lieberman J.A., Stroup T.S., McEvoy J.P., et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
4. Liu-Seifert H., Adams D.H., and Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 3 (2005) 21
5. Valenstein M., Blow F.C., Copeland L.A., et al. Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors. Schizophr Bull 30 (2004) 255-264
6. Al-Zakwani I.S., Barron J.J., Bullano M.F., et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 19 (2003) 619-626
7. Diaz E., Neuse E., Sullivan M.C., et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatr 65 (2004) 354-360
8. Eaddy M., Grogg A., and Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 27 (2005) 263-272
9. Ward A., Ishak K., Proskorovsky I., and Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther 28 (2006) 1912-1921
10. Conley R.R., and Kelly D.L. Drug-drug interactions associated with second-generation antipsychotics: Considerations for clinicians and patients. Psychopharmacol Bull 40 (2007) 77-97
11. Bork J.A., Rogers T., Wedlund P.J., and de Leon J. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60 (1999) 469-476
12. Sharif Z.A. Pharmacokinetics, metabolism and drug-drug interactions of atypical antipsychotics in special populations. Prim Care Companion J Clin Psychiatry 5 Suppl 6 (2003) 22-25
13. Sandson N.B., Armstrong S.C., and Cozza K.L. An overview of psychotropic drug-drug interactions. Psychosomatics 46 (2005) 464-494
14. Riedel M., Schwarz M.J., Strassing M., et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255 (2005) 261-268
15. Spina E., Avenoso A., Scordo M.G., et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22 (2002) 419-423
16. de Leon J., Susce M.T., Pan R.M., et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66 (2005) 15-27
17. Spina E., Avenoso A., Facciolà G., et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23 (2001) 223-227
18. Risperidol (risperidone) [product monograph]. Compendium of Pharmaceuticals and Specialties (2007), Canadian Pharmacists Association, Ottawa, Canada 2093-2099
19. Electronic Compendium of Pharmaceutical Specialties. Clin-Info: Cytochrome P450 drug interactions.
20. (January 24, 2008). https://www.e-therapeutics.ca/wps/myportal/!ut/p/_s.7_0_A/7_0_2V5/.cmd/acd/.ar/sa.TOCACTION/.c/6_0_2KO/.ce/7_0_2VB/.p/5_0_288/.d/0?PC_7_0_2VB_value=clininfoN1001A%3A%3ACytochrome+P450+Drug+Interactions#7_0_2VB Accessed
21. Boom S, De Vries D, Eerdekens M, et al. Effect of CYP3A4 inhibition on the pharmacokinetics of risperidone and 9-hydroxy-risperidone enantiomers in man. Presented at: 41st Annual Meeting of the American College of Neuropsychopharmacology; December 8-12, 2002; San Juan, Puerto Rico. Abstract NO-W-133.
22. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
23. Kelsey J.L., Whittemore A.S., Evans A.S., and Thompson W.D. Methods in Observational Epidemiology. 2nd ed (1996), Oxford University Press, New York, NY
24. Tamblyn R., Lavoie G., Petrella L., and Monette J. The use of prescription claims databases in pharmacoepi-demiological research: The accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol 48 (1995) 999-1009
25. Rawson N.S., Malcolm E., and D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc Psychiatry Psychiatr Epidemiol 332 (1997) 1191-1199